1. Results {#s0005}
==========

The search yielded 181 unique articles. From this, 162 articles were selected for full text review and 35 articles met inclusion criteria and were included in the final rapid review synthesis. A total of 35 studies (including 12 prospective cohorts, 18 retrospective cohorts, and 5 case reports) with 414 patients were synthesized (see [Table 1](#t0005){ref-type="table"} *and Table 2*) \[[@bb0050], [@bb0055], [@bb0060], [@bb0065], [@bb0070], [@bb0075], [@bb0080], [@bb0085], [@bb0090], [@bb0095], [@bb0100], [@bb0105], [@bb0110], [@bb0115], [@bb0120], [@bb0125], [@bb0130], [@bb0135], [@bb0140], [@bb0145], [@bb0150], [@bb0155], [@bb0160], [@bb0165], [@bb0170], [@bb0175], [@bb0180], [@bb0185], [@bb0190], [@bb0195], [@bb0200], [@bb0205], [@bb0210], [@bb0215], [@bb0220]\]. Twenty-nine of these studies (*n* = 364 patients; 11 prospective cohorts, 13 retrospective cohorts, 5 case reports) report on the use of awake prone positioning in COVID-19 patients \[[@bb0050], [@bb0055], [@bb0060], [@bb0065], [@bb0070], [@bb0075], [@bb0080], [@bb0085],[@bb0095], [@bb0100], [@bb0105],[@bb0120], [@bb0125], [@bb0130], [@bb0135], [@bb0140], [@bb0145],[@bb0155], [@bb0160], [@bb0165],[@bb0175], [@bb0180], [@bb0185], [@bb0190], [@bb0195],[@bb0205], [@bb0210], [@bb0215], [@bb0220]\]. Only one study included data from a control group \[[@bb0220]\]. Seventeen studies (128 patients) were conducted exclusively within the ICU \[[@bb0060],[@bb0080], [@bb0085], [@bb0090], [@bb0095],[@bb0110],[@bb0115],[@bb0125],[@bb0145], [@bb0150], [@bb0155],[@bb0170],[@bb0175],[@bb0185],[@bb0200], [@bb0205], [@bb0210]\], two in the emergency department (60 patients) \[[@bb0050],[@bb0065]\], eight exclusively on a non-ICU hospital ward (104 patients) \[[@bb0070],[@bb0100],[@bb0105],[@bb0135],[@bb0140],[@bb0160],[@bb0165],[@bb0190]\], and two studies included patients in multiple settings (73 patients) \[[@bb0075],[@bb0180]\]. The setting was not reported in 6 studies (49 patients) \[[@bb0055],[@bb0120],[@bb0130],[@bb0195],[@bb0215],[@bb0220]\]. The frequency and duration of prone positioning was protocolized in only 15 studies (223 patients) \[[@bb0050],[@bb0070], [@bb0075], [@bb0080],[@bb0090],[@bb0095],[@bb0125],[@bb0130],[@bb0140],[@bb0150],[@bb0155],[@bb0190],[@bb0195],[@bb0215],[@bb0220]\]. The duration of prone positioning sessions varied from \<1 h to \>18 h ([Tables 1](#t0005){ref-type="table"} and 2) and was not reported in three studies \[[@bb0065],[@bb0130],[@bb0135]\]. All studies demonstrated improvements in oxygenation while patients were in the prone position except one \[[@bb0085]\]. When reported, improvements in oxygenation were generally not sustained after returning to the supine position, \[[@bb0075],[@bb0100],[@bb0155],[@bb0170], [@bb0175], [@bb0180]\] except in two studies in which patients were receiving NIV \[[@bb0165],[@bb0200]\]. One hundred twenty-one patients (29%) of the 414 patients (35 studies) required invasive mechanical ventilation. Adverse events were variably reported and included 42 deaths among the 414 patients (10.1% of all patients), discomfort, nosebleeds, sternal pain, back pain, and intolerance of awake prone positioning. Follow-up duration was variably reported ([Tables 1](#t0005){ref-type="table"} and 2) and was not reported in eight studies \[[@bb0085],[@bb0090],[@bb0110], [@bb0115], [@bb0120], [@bb0125],[@bb0150],[@bb0155]\]. (See [Table 2](#t0010){ref-type="table"} .)Table 1Characteristics of studies examining awake prone positioning in non-intubated patients with hypoxemic respiratory failure due to COVID-19.Table 1horStudy TypeNInclusion CriteriaExclusion CriteriaSettingOxygen Delivery ModeProne Positioning ProtocolStudy OutcomeDuration of Follow-upDuration of Prone PositioningSupine Oxygenation and Resp Rate (if available)\
mean (SD), median \[IQR\]Prone Position Oxygenation and Resp Rate (if available) mean (SD), median \[IQR\]Intubation Rate, No. (%)Adverse Event ReportingCoppo (2020)PC56Age 18--75, confirmed COVID-19, hypoxemia consentPregnant, uncollaborative, altered mental status, NYHA \< II, increased BNP, COPD on home NIV or O~2~, impending intubationNon-ICU Medical units, ED, ICUHelmet CPAP, Reservoir mask, Venturi maskAssisted proning, encouraged to maintain x 3 h, Repeat up to 8 h/dPaO~2~:FiO~2~Hospital dischargeMedian 3 h \[3, 4\]\
Up to 7 sessions.PaO~2~:FiO~2~ 180.5 (76.6)\
RR 24.5 (5.5)PaO~2~:FiO~2~ 285.5 (112.9)\
RR 24.5 (6.9)18/56 (32)9% discomfort\
4% worsening oxygenation\
2% coughing\
5 deaths (9%)Golestani-Eraghi (2020)PC10COVID-19, not mech ventilated, PaO~2~:FiO~2~ \< 150Not reportedICUHelmet NIV2 h sessionsNot reportedNot reportedMean 9 hPaO~2~ 46.3 (5.2)PaO~2~ 62.5 (4.6)2/10 (20%)None reported\
2 deaths (20%)Moghadam (2020)PC10COVID-19, not mech ventilatedNot reportedNon-ICU Medical unitNot reportedNot reportedSpO2, RR, auxiliary muscle useHospital dischargeNot reportedSpO~2~ 86% (0.7)SpO~2~ 96% (2.2)0/10 (0)Not reportedElharrar (2020)PC24Hypoxemia, CT chest with COVID-19 and posterior lesionsRequiring intubation, altered consciousnessNon-ICU Medical unitNP, facemask, HFNCSingle episode, no goal durationProportion of patients with PaO~2~ increase ≥20%from supine to PP10 days17% \<1 h\
21% 1--3 h\
63% \>3 hPaO~2~ 72.8 (14.2)PaO~2~ 91 (27.3)\
25% had ≥20% increase PaO25/24 (20.8)42% backpain\
17% tolerated \<1 h\
17% required intubation within 72 hNg (2020)PC10HypoxemiaDrowsy, uncooper-ative, ophthalmic or cervical pathology, pregnancy, hemodyn-amic instability, FiO~2~ \> 0.5Non-ICU Medical unitNP, HFNC, or Venturi mask1 h sessions, 5 sessions/d\
spaced 3 h apart. Continued until on RA x 24 hNot reportedMedian 8 days (range 2--19)Median total duration 21 h (range 2--58)SpO~2~ 91.5 (range 88--95)Not reported1/10 (10)Discomfort, nausea, vomiting reported\
1 death (10%)Retucci (2020)PC26COVID-19, spontane-ous breathing, GCS = 15, PaO~2~:FiO~2~ \< 250 after 48 h Helmet CPAPRequiring intubation, GCS \< 15, SBP \< 90, SpO~2~ \< 90% on FiO~2~ \> 0.8ICUHelmet CPAPProne/lateral positioning based on CXR or CT scan, 1 h sessions.\
39 sessions:\
12 prone, 27 lateralSuccessful trial, defined as all 4 of:\
1. decrease A-aO~2~ gradient ≥20%, 2. equal or reduced RR, 3. equal or reduced dyspnea\
4. SBP ≥ 90 mmHgNot reported1 hPaO~2~:FiO~2~ 182.9 (43)\
A-aO~2~ 207.1 \[160.7--251.3\]\
RR 23.7 (4.7)PaO~2~:FiO~2~ 220 (64.5)\
A-aO~2~ 184.3 \[141.4--246.8\]\
RR 23.1 (4.5)7/26 (27)39% of trials did not meet primary outcome.\
25% of prone position trials failed\
40% of lateral position trials failed\
8% did not tolerate (both in lateral position)\
5% discomfort\
3% SBP \< 90 mmHg\
8% increased RR\
2 deaths (8%)Sartini (2020)PC15Hypoxemia (SpO~2~ \< 94%), FiO2 \> 0.6 and CPAP 10 cm H~2~O--Non-ICU Medical UnitNIVNot reportedPaO~2~:FiO~2~, RR, patient comfort with NIV14 daysMedian 3 h (IQR 1--6)PaO~2~:FiO~2~ 58--117\*\*\
Supine RR: 21--31\*\*PaO~2~:FiO~2~ 114--122\*\*\
PP: 18--27\*\*1/15 (6.6)1 death (7%)Thompson (2020)PC29Confirmed COVID-19, Severe hypoxemia (RR \> 30 and SpO~2~ \< 93% on 6 L O~2~ by NP and 15 L by NRBAltered mental status, inability to turn without help, immediate intubation needed, mild hypoxemia.Step-down unit (interme-diate)NP or NRBRepeated episodes, up to 24 h per day, use a pillow under hips/pelvis.Change in SpO~2~ at 1 hUp to 49 days or to hospital dischargeMedian 4 h (range 1--24) in not-intubated group, Median 6 h (range 1--24) in intubated group.\
SpO~2~ 65--95%\*\*SpO~2~ 90--100%\*\*\
Median SpO~2~ improvement 7% \[4.6--9.4\]16/29 (55)13% refused\
3 deaths (10%)Tu (2020)PC9COVID-19 confirmed, HFNC \>2 days, PaO~2~:FiO~2~ \< 150--Not reportedHFNCRepeated episodes, as long as toleratedSpO~2~\
PaO~2~Hospital discharge, mean LOS 28 (10) dMedian 2 h \[1--4\] per session, median 5 \[3--8\] sessionsSpO~2~ 90% (2)\
PaO~2~ 69 (10)SpO~2~ 96% (3)\
PaO~2~ 108 (14)2/9 (22)None reported\
1 intubated patient required ECMO\
0 deaths (0%)Caputo (2020)PC50Hypoxemia (SpO~2~ \< 90%)NIV use, DNR orderEDNP or facemaskNot reportedSpO~2~ 5 min after PP, intubation rate within 24 h3 daysNot reportedSpO~2~ 84% \[75--90\]SpO~2~ 94% \[90--95\]13/50 (26.0)22% required intubation within 60 minZhang (2020)PC23COVID-19, Hypoxemia (SpO~2~ \< 90%), Age 18--80, consentNeed for intubation, inability to self position, basal lung disease, unstable spine, high ICP, severe burns, abdo surgery, abdo HTN, cranial injury, tracheotomy, immuno-suppresion, pregnant, imminent death.Not reportedNP, HFNC, NIVEvaluated muscle strength first, self position prone, 1-2 h sessions 3--4 times/day for 5 days. Vitals measured at 10 min and 30 min in PPSpO2, RR, ROX90 daysMedian 9 h \[8--22\]SpO~2~ 91.1 (1.5), RR 28.2 (3.1)\
ROX 3.35 (0.46)SpO~2~ 95.5 (1.7)\
RR 24.9 (1.8)\
ROX 3.96 (0.45)8/23 (35)10 deaths (43%)Bastoni (2020)RC10Receiving helmet NIV, awake & able to proneNeed for rapid intubation & ICU, End-stage comorbid diseaseEDHelmet CPAP 10--20 cmH2ONurse assisted, Morphine infusion for sedation.PaO~2~:FiO~2~, Lung US signsHospital discharge1 hPaO~2~:FiO~2~ 68 (5)PaO~2~:FiO~2~ 97 (8)\
No change in lung US findings6/10 (60)40% did not tolerate or refused.\
4 deaths (40%)Burton-Papp (2020)RC20COVID-19, Hypoxemia, received CPAP or NIV--ICUCPAP or NIVNot describedΔP/FHospital dischargeMedian 3 \[2\]\
Median 5 cycles per patient \[6.25\]--ΔPaO~2~/FiO~2~ + 28.7 \[95%CI 18.7--38.6\]\
ΔRR −0.98 \[95%CI -2-0.04\]7/20 (35)None reported\
2 intubated patients required ECMO\
0 deathsCohen (2020)RC252 Female\
40 Male--Non-ICU Medical unitHFNC, NPSelf-prone as long as possible--Discharge from unit2--4 h per dayPatient 1. SpO~2~ 90% on HFNC FiO2 1.0, RR 45\
Patient 2. SpO~2~ 92% on 4 LPatient 1. SpO~2~ 100% on HFNC FiO2 1.0, RR 25\
Patinet 2. SpO~2~ 96% on 2 L0/2 (0)None reportedDamarla (2020)RC10Confirmed COVID-19, rapidly increasing O~2~ requiring ICURequiring intubationICUNP or HFNCAlternate prone/supine every 2 h, supervised first episodeSpO~2~, RR at 1 h28 d2 hSpO~2~ 94% \[91--95\]\
RR 31 \[28--39\]SpO~2~ 98 \[97--99\]\
RR 22 \[18--25\]2/10 (20)None\
0 deathsDespres (2020)RC6COVID-19, PaO~2~:FiO~2~ ≤ 300Requiring intubationICUNP, HFNCAs long as toleratedPaO~2~:FiO~2~Not reportedMedian 2 h \[1--7\]PaO~2~:FiO~2~ 183 \[144--212\]PaO~2~:FiO~2~ 168 \[156--225\]3/6 (50%)Not reportedDong (2020)RC25COVID-19, Severe disease (RR ≥ 30, SpO2 ≤ 93% or PaO~2~:FiO~2~ 〈300), or critical disease (Requiring ventilation, shock, organ failure)Excluded patients who received PP but rapidly improved or who did not tolerate first session.ICUNP, Mask, HFNC, NIVDaily session \>4 h, nurse instructions, lateral positioning if PP not toleratedSurvival, intubation, PaO~2~:FiO~2~Hospital dischargeMean 4.9 h (SD 3.1)PaO~2~:FiO~2~ 194 \[164--252\]\
RR 27 \[26--30\]PaO~2~:FiO~2~ 348 \[288--390\]\
RR 22 \[20−22\]0/2516% Sternal pain\
4% Scrotal pain\
4% Lumbago\
4% Pruritis\
0 deathsFroelich (2020)RC3Confirmed COVID-19--Not reportedNP. Face Mask, HFNCVaried positions, supine, lateral, prone, ergonomic prone.SpO~2~Not reported\<30 minPatient 1. SpO~2~ 94% on 4 L\
Patient 2. SpO~2~ 95% on 6 L\
Patient 3. SpO~2~ 91% on 15 LPatient 1. SpO~2~ 97% on 4 L\
Patient 2. SpO~2~ 97% on 6 L\
Patient 3. SpO~2~ 95% on 15 L (lateral position only)0/3 (0)33% Hip and back pain\
33% Inability to maintain prone position due to jaw dislocationHuang (2020)RC3SpO~2~ \< 92% on ≥6 L or PaO~2~:FiO~2~ \< 200, bilateral opacities, RR \< 30Accessory muscle use, Contraindic-ations (cervical instability, pregnancy)Not reportedHFNC, Venturi maskFour 2 h sessions dailyPaO~2~:FiO~2~Up to 6 daysNot reportedPatient 1. PaO~2~:FiO~2~ 84.8\
Patient 2. PaO~2~:FiO~2~ 160\
Patient 3. PaO~2~:FiO~2~ 60.6Patient 1. PaO~2~:FiO~2~ 114\
Patient 2. PaO~2~:FiO~2~ 169\
Patient 3. PaO~2~:FiO~2~ 1331/3 (33)Not reportedPaul (2020)RC242 Male\
35 Male--ICUHFNC, NIVNot reported--Hospital discharge2--3 h sessions, over 3 daysPatient 1. SpO~2~ 92% on FiO~2~ 0.7\
Patient 2. FiO~2~ 0.8Patient 1. SpO~2~ 98% on FiO~2~ 0.5\
Patient 2. FiO~2~ 0.40/2 (0)Anxiety and discomfort in both patientsRipoll-Gallardo (2020)RC13PaO~2~:FiO~2~ \< 150Requiring intubation, hemodyn-amic instability, multiorgan failureNon-ICU Medical unitHelmet CPAPEncouraged as long as possiblePaO~2~:FiO~2~Hospital dischargeMean 2.4 h (SD 0.87)PaO~2~:FiO~2~ 113 \[108--121\]PaO~2~:FiO~2~ 138 \[126--178\]9/13 (69)No complications\
7 deaths (54%)Solverson (2020)RC17Suspected or confirmed COVID-19, ICU consult, Hypoxemia (5 L to maintain SpO2 ≥ 90%), at least 1 prone session--ICU, non-ICU medical wardNP, HFNCEncouraged as long as possibleSpO~2~\
TolerabilityHospital discharge35% \< 1 h\
Median 75 min (range 30--480), Median 2 sessions (range 1--6) per daySpO~2~ 91% (range 84--95)\
RR 28 (range 18--38)\
SpO~2~:FiO~2~ 152 (range 97--233)SpO~2~ 98% (range 92--100)\
RR 22 (range 15--33)\
SpO~2~:FiO~2~ 165 (range 106--248)7/17 (41)47% pain/discomfort\
6% delirium\
2 deaths (12%)Sztajnbok (2020)RC243 Male\
37 Male--ICUNRBEncouraged as long as possible--ICU discharge8--10 h, single sessionsPatient 1. SpO~2~ 100% on 10 L, RR 30\
Patient 2. SpO~2~ 94% on 10 L, RR 28Patient 1. Decreased to 5 L\
Patient 2. SpO~2~ 96% on 3 L, RR 220/2 (0)Not reportedXu (2020)RC10COVID-19 confirmed,Not reportedTarget 16 h/d, target SpO~2~ \> 90%PaO~2~:FiO~2~Hospital discharge, mean LOS 17.7 d4--6 h sessionsPaO~2~:FiO~2~ 89--228PaO~2~:FiO~2~ 200--325\*\* on day 3 of PP0/10 (0)0 deathsCascella (2020)CR154 Male\
Received tocilizumab--Not reportedNIV3 sessions per dayPaO~2~:FiO~2~Hospital dischargeMean 90 min per sessionPaO~2~:FiO~2~ 150PaO~2~:FiO~2~ 3000/1 (0)Not reportedVibert (2020)CR123 Female\
pregnant\
Hypoxemia--ICUHFNC and NIVNot reported--Hospital discharge2 h periodsSpO~2~ 89%, FiO~2~ 0.6, 60 L/minSpO~2~ 96%, FiO~2~ 0.6, 60 L/min0/1 (0)No adverse patient or fetal eventsElkattawy (2020)CR136 Male Hypoxemia--Non-ICU Medical unitNPNot reported--1 day\>12 h per daySpO~2~ 94%, 4 L/min NPSpO~2~ 95%, room air0/1 (0)Not reportedSlessarev (2020)CR168 Male Hypoxemia--ICUHFNCNot reported--4 days16--18 h per dayPaO~2~:FiO~2~ 100\*\*PaO~2~:FiO~2~ 250\*\*0/1 (0)1 NosebleedWhittemore (2020)CR160 Male Hypoxemia--ICUNRBNot reportedSpO~2~Hospital discharge\>18 h per daySpO~2~ 82% on 12 L NRBSpO~2~ 94% on 12 L NRB0/1Not reported[^2]Table 2Characteristics of Studies Examining Awake Prone Positioning in Non-intubated Patients with Hypoxemic Respiratory Failure not due to COVID-19.Table 2AuthorStudy TypeNInclusion CriteriaExclusion CriteriaSettingOxygen Delivery ModeProne Positioning ProtocolStudy OutcomeDuration of Follow-upDuration of Prone PositioningSupine Oxygenation and Resp Rate (if available)\
mean (SD), median \[IQR\]Prone Position Oxygenation and Resp Rate (if available)\
mean (SD), median \[IQR\]Intubation Rate, No. (%)Adverse Event ReportingDing (2020)PC20ARDS (Berlin) on NIV with CPAP 5 cm H~2~O and PaO~2~:FiO~2~ \< 200Requiring intubationICUHFNC or NIV\>30 min, 2 times daily for 3 daysIntubation rate, change in PaO~2~:FiO~2~Not reportedMean 2 hPaO~2~:FiO~2~ 95 (22) / 102 (15)\*PaO~2~:FiO~2~ 130 (35) / 113 (25)\*9/20 (45.0)2 non-tolerant\
1 death (5%)Perez-Nieto (2020)RC6ARDS (Berlin criteria) non-infections ARDS, and PaO~2~:FiO~2~ \< 100--ICUHFNC or NIV2--3 h, 2 times daily for 2 days--Not reported2--3 h every 12 hPaO~2~:FiO~2~ 80\
\[67--91\]PaO~2~:FiO~2~ 116\
\[101−131\]2/6 (33.3)1 death (17%)Scaravilli (2015)RC15PaO~2~:FiO~2~ \< 300, and undergone one PP without intubation--ICUNP, HFNC or NIVNot reportedChange in PaO~2~:FiO~2~Hospital dischargeMedian 3 (IQR 2--4)PaO~2~:FiO~2~ 127(49)\
RR: 26 (10)PaO~2~:FiO~2~ 186 (72)\
RR: 25 (11)2/15 (13.3)No displaced catheters, pressure sores, neuropathy, vomiting, change in hemodynamics or vasopressors\
2 patients non-tolerant, 3 patients died without intubation: 2 patients put on ECMO before intubation, and 1 patient changed goals of careFeltracco (2012)RC3Post lung transplant, and hypoxemia--ICUHFPVNot reported--Not reported1--3 h 5--6 times per day, 1 h 3--4 times per\
Day----0/1 (0)Not reportedFeltracco (2009)RC2Post lung transplant, and hypoxemia--ICUNIVNot reported--Not reported6-8 h per dayFiO~2~ 0.80FiO~2~ 0.600/1 (0)Not reportedValter (2003)RC4Hypoxemia--ICUNIVNot reported--Hospital discharge1--5 hFiO~2~ 0.70 \[0.60--0.70\]\
RR: 31 (26--38)FiO~2~ 0.40 \[0.30--0.50\]\
RR: 20 (18--21)0/1 (0)Not reported

2. Discussion {#s0010}
=============

In this rapid review, we present a synthesis of 35 studies (414 patients) that examined the use of awake prone positioning for non-intubated patients with hypoxemic respiratory failure. There has been significant attention on its use as a potential treatment for COVID-19 through news organizations, social media, and institutional guidelines. However, the evidence to support prone positioning in this population is limited to uncontrolled prospective or retrospective cohorts and case reports with small sample sizes and limited follow-up.

The cohorts and case studies in this rapid review describe an improvement in oxygenation while patients were in the prone position. The impact of improved oxygenation on clinical outcomes such as survival remains unclear. In contrast to non-intubated patients, prone positioning invasively ventilated patients with moderate-severe ARDS within an ICU is a proven life-saving intervention and is supported by meta-analyses of randomized control trials \[[@bb0020],[@bb0225],[@bb0230]\]. Although many invasively ventilated patients improve their oxygenation when in the prone position, these changes are not associated with survival \[[@bb0235]\]. The survival benefit is more likely mediated through a reduction in ventilator induced lung injury and not improved oxygenation \[[@bb0235]\]. Given that non-intubated patients are not at risk for ventilator induced lung injury, potential clinical benefits may be mediated through improved oxygenation, preventing intubation (which can be influenced by clinician decision making and bias), reduced respiratory work, or a reduction in patient self-inflicted lung injury \[[@bb0240]\].

In this synthesis, many patients receiving awake prone positioning were treated in monitored settings and not general wards (182 of 414 patients, 44%). Key details to offer this intervention safely such as the frequency, duration and adverse events were often not described or provided in limited detail. In six studies, awake prone positioning was not tolerated by some patients for even short durations \[[@bb0050],[@bb0090],[@bb0100],[@bb0120],[@bb0170],[@bb0180]\]. Invasively ventilated patients with ARDS require greater than 12 h of prone positioning to receive a mortality benefit from prone positioning, which often requires sedation and paralysis to be tolerated \[[@bb0225],[@bb0230]\]. Furthermore, patients included in this rapid review were heterogeneous in terms of hypoxemia severity. Prone positioning invasively ventilated patients is only beneficial in moderate-severe ARDS, not all severities of hypoxemia \[[@bb0225]\].

In summary, although awake prone positioning may be a promising therapy for patients with hypoxemic respiratory failure (including those with COVID-19), the supporting evidence is limited to case reports and cohort studies. These studies when synthesized highlight the lack of key details to inform clinicians and trialists. Many questions remain unanswered when considering the use of awake prone positioning. What are the effects on patient outcomes? What is the optimal frequency and duration? What are the criteria for stopping prone positioning? Which patients are most likely to benefit and which ones should be excluded? What are the potential adverse events that could occur? Ongoing randomized controlled trials ([NCT04402879](NCT04402879){#ir0005}, [NCT04383613](NCT04383613){#ir0010}, [NCT04383613](NCT04383613){#ir0015}, [NCT04350723](NCT04350723){#ir0020}, [NCT04365959](NCT04365959){#ir0025}, [NCT04347941](NCT04347941){#ir0030}) will be crucial in answering these questions.
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Supplementary materialImage 1

[^1]: JW and KS contributed equally.

[^2]: \* High flow nasal cannula success/failure, \*\* Range, estimated from a figure. Abbreviations: ARDS, acute respiratory distress syndrome; BNP, B-type natriuretic peptide; CPAP, continuous positive airway pressure; CR, case report; CT, computed tomography; DNR, do not resuscitate; ECMO, extracorporeal membrane oxygenation; ED, emergency department; FiO~2~, fraction of inhaled oxygen; GCS, Glasgow Coma Scale; HFNC, high-flow nasal cannula; HFPV, high-frequency percussive ventilation; HTN, hypertension; ICP, intracranial pressure; ICU, intensive care unit; IQR, interquartile range; LOS, length of stay; NIV, non-invasive ventilation; NP, nasal prongs; NRB, non-rebreather face mask; NYHA, New York Heart Association; PaO~2~, partial pressure of arterial oxygen; PC, prospective cohort; PP, prone position; RC, retrospective cohort; RA, room air; ROX, ROX index = SpO2/FiO2 x 1/respiratory rate; RR, respiratory rate; SBP, systolic blood pressure; SD, standard deviation; SpO~2~, oxygen saturation; US, ultrasound.
